1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,350 | 8,750 | 17:53 | |
| 8,350 | 8,750 | 17:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:09 | Keymed Biosciences Announces 2026 H1 Results and Business Updates | 212 | PR Newswire | CHENGDU, China, Aug. 20, 2026 /PRNewswire/ -- On August 19, 2026, Keymed Biosciences (HKEX: 02162) announced its interim results for the six months ended June 30... ► Artikel lesen | |
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 04:17 | KEYMED BIO-B Surges Over 6% as Interim Results Swing to Profit, Plans STAR Market Listing in Shanghai | 5 | AASTOCKS | ||
| 03:47 | KEYMED BIO-B Swings to Interim Profit of RMB1.218 Billion | 2 | AASTOCKS | ||
| Mi | KEYMED BIO-B (02162): INSIDE INFORMATION - PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE | 1 | HKEx | ||
| Mi | KEYMED BIO-B (02162): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 | - | HKEx | ||
| 10.08. | KEYMED BIO-B to Launch Phase III Clinical Study of CM512 for Chronic Rhinosinusitis | 1 | AASTOCKS | ||
| 10.08. | KEYMED BIO-B (02162): INSIDE INFORMATION ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CM512 (TSLP X IL-13 BISPECIFIC ANTIBODY) INJECTION FOR PATIENTS WITH ... | 2 | HKEx | ||
| 07.08. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | 2 | HKEx | ||
| 28.07. | KEYMED BIO-B CMG901 (AZD0901) Global Phase III Trial Delivers Positive Topline Results | 1 | AASTOCKS | ||
| 28.07. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - CMG901 (AZD0901) CLARITY-GASTRIC01 GLOBAL PHASE III CLINICAL TRIAL ACHIEVES POSITIVE TOPLINE RESULTS | 2 | HKEx | ||
| 23.07. | KEYMED BIO-B CM512 Included in Breakthrough Therapy Designation List by NMPA's Center for Drug Evaluation | 2 | AASTOCKS | ||
| 23.07. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - CM512 INCLUDED IN THE BREAKTHROUGH THERAPY DESIGNATION LIST BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL ... | 1 | HKEx | ||
| 15.07. | KEYMED BIO-B (02162): INSIDE INFORMATION ANNOUNCEMENT - (1) UPDATE ON PRODUCT REVENUE FOR THE FIRST HALF OF 2026 AND (2) POSITIVE PROFIT ALERT | - | HKEx | ||
| 26.06. | KEYMED BIO-B (02162): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 05.06. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - UPDATE ON DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | 2 | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ... | 1 | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 15.04. | KEYMED BIO-B (02162): SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | - | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,356 | -1,41 % | Evotec-Aktie verliert nach schwachen Halbjahreszahlen | Evotec hat Zahlen für das erste Halbjahr veröffentlicht. Der Umsatz bricht ein und die Verluste steigen, doch ab Q4 setzt der Konzern auf eine Trendwende. Der Wirkstoffforscher Evotec hat im ersten... ► Artikel lesen | |
| BB BIOTECH | 58,40 | -1,35 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MODERNA | 119,88 | -19,88 % | Termin-Börse daily: Unser Moderna-Call explodiert um 420 % - hier ist der Grund | MODERNA schießt heute vorbörslich um rund 100 % nach oben. Auslöser sind positive Phase-III-Daten für den gemeinsam mit MERCK entwickelten mRNA-Krebsimpfstoff gegen Melanome. Nach Angaben des Unternehmens... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,83 | -0,94 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| NANOREPRO | 1,885 | -0,79 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
18.08.2026 / 07:30... ► Artikel lesen | |
| AAP IMPLANTATE | 1,480 | +2,07 % | EQS-News: aap Implantate AG: aap verbessert Profitabilität im ersten Halbjahr 2026 und startet mit Rekordauftragseingang in die zweite Jahreshälfte | EQS-News: aap Implantate AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
aap verbessert Profitabilität im ersten Halbjahr 2026 und startet mit Rekordauftragseingang in... ► Artikel lesen | |
| INFLARX | 1,780 | -2,20 % | InflaRx NV: Durchbruch in der Immuntherapie weckt weltweites Interesse | ||
| TEMPUS AI | 58,90 | +12,34 % | Tempus AI stock is soaring and it has Moderna to thank | ||
| EDITAS MEDICINE | 2,690 | -3,24 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 58,60 | -1,35 % | BioMarin Pharmaceutical Inc.: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline | BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones
Alesta to spin out all non-ALE1 assets... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,582 | -4,35 % | Cardiol Therapeutics GAAP EPS of -C$0.05 | ||
| EVONEXT | 2,540 | -3,05 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA confirms advanced discussions on a reverse merger with Ascend Sport Technology AG
17-Aug-2026 / 17:50 CET/CEST
Release of... ► Artikel lesen | |
| IDORSIA | 5,930 | -4,82 % | Idorsia Pharmaceuticals Ltd: Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule - Schedule V | Ad hoc announcement pursuant to Art. 53 LR
The DEA states that dual orexin receptor antagonists "do not produce physical or psychological dependence"Lower schedule expected to enhance patient access... ► Artikel lesen | |
| MYRIAD GENETICS | 2,758 | +2,45 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| ALDEYRA | 1,340 | -1,47 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report |
KEYMED BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,450 Euro und damit +1,20 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.